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A 5 kilobasc deletion in mitochondrial DNA (mtDNA) has been reported to be responsible for the specific complex I deficiency in the substantia 
nigra (SN) of the Parkinson’s disease (PD) brain. We have studied mitochondrial respiratory chain function in the SN from control and PD subjects, 
and analysed mtDNA. extracted from the same tissues, by Southern blot and the polymerase chain reaction (PCR). Quantitation of the levels of 
the deletion indicate that it does not contribute to the pathogenesis of PD nor tc a ccmplex I deficiency but seems likely to be an age-related 
observation. 
NADh CoQ, reductasc; Parkinson’s disease; Mitochondrion; Mitochondrial DNA 
1. iNTRODUCTION 
Idiopathic Parkonson’s disease (PD) is a common 
neurodcgenerative disease characterised pathologically 
by the loss of dopaminergic neurones in the substantia 
nigra and the presence of Lewy bodies in some surviving 
neurones. The cause of the cell death underlying PD is 
unknown. However, the discovery that the neurotoxin, 
1-methyl4-phenyl 1,2,3,6 tetrahydropyridine (MPTP) 
can induce Parkinsonism in humans [l] has provided a 
valuable insight into the possible pathogenic mecha- 
nism(s) of PD. MPTP is converted to its active metabo- 
lite l-methyl-4-phenylpyridinium (MPP’), by glial mo- 
noamine oxidase B [2], which enters dopaminergic 
neurones via the dopamine re-uptake system [3]. Once 
inside the neurones it is actively concentrated into mi- 
tochondria where it specifically inhibits NADH CoQ, 
reductase (complex I) activity [4], The inhibition of 
complex I leads to a fall in ATP production, which 
ultimately results in cell death [5]. 
Complex I activity has been reported to be decreased 
in the substantia nigra of the PD brain [6j and appears 
to be anatomically specific to the substantia nigra and 
disease-specific to PD [7], These observations have 
focused attention on the possible role of abnormal mito- 
chondrial function in the pathogenesis of PD. 
Complex I dysfunction in PD sabstantia nigra could 
be the resuh of some endogenous or exogenous toxic 
agent or be due to a mutation in one or more of the 
nuclear or mitochondrial genes for complex I subunits. 
Such mutations may be primary or secondary to some 
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process such as oxidative stress, to which mtDNA is 
particularly susceptible because of its lack of repair en- 
zymes [S]. Complex I is the Alost vulnerable respiratory 
chain complex to indiscriminate damage to mtDNA 
because of its high proportion of mtDNA encoded sub- 
units. 
A 5 kilobase (kb) deletion in mtDNA has been found 
in several neuromuscular diseases associated with mito- 
chondrial dysfunction [9], and is referred to as the ‘com- 
mon deletion’. This deletion has been observed to in- 
crease with age [lo]. The deletion includes genes for 
complex I, IV and V subunits as well as numerous 
tRNAs, and is flanked by 13 bp direct repeats [ 111 which 
are thought to render this area prone to deletion via slip 
replication. 
Restriction fragment length polymorphism (RFLP) 
analysis of mtDNA in PD brain failed to show any 
major deletions [ 12,131. Polymerase chain reaction 
(PCR) amplification of the common deletion in PD 
striatum, however, has suggested that there is a lbfold 
accumulation compared to control striatum [14]. Such 
a result, if confirmed, would have important implica- 
tions for our understanding of the role of intDNA in the 
aetiology of PD. We have therefore analysed mtDNA 
from the substantia nigra of control and PD patients via 
Southern blotting and PCR. 
2. METHODS 
2, !. Biuchmislry 
Parkinson patients and controls were matched for age, death to 
refrigeration and death to autopsy time. The substantia nigra from six 
patients who had died with idiopathic Parkinson’s disease and from 
six controls was homogenised [6], snd protein content and enzyme; 
aclivities in brain homogenates were determined as previously de- 
scribed [7]. 
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22. Prqwurion QJ DNA 
Bruin homogenates were lysed with OS% SDS in 75 mM NaCI, SO 
mM EDTA, pH 8.0, and digested overnight with 2 mdml protcinase 
K at 37°C. DNA was extracted twix with phenol followed by chlo- 
roform: isoamyl alcohol (241). precipitated with a 0.1 vol. of 3 M 
aodium acetate and 2 vol. of absolute thanol at -70°C ror 30 min. 
centrifuged at 12,000 xg for 15 min and the pellets rinsed with ice-cold 
70% ethanol. The precipitated DNA was dissolved in 1 mM Tris, 0.1 
mM EDTA, pH 8.0. 
2.3. Sottrhrrtt blnr ntial.vsis 
2 pug or total DNA was digested with &II (NBL, UK) with the 
addition of bovine serum albumin (0.1 mg/ml) and spermidine (IO 
mM). Digested DNA was electrophorcsed through a 0.8% agarose gel, 
and transferred to nylon membrane (Hybond-N, Amersham, UK) 
[IS]. Prehybridisatior, and hybridisation, with ‘?P~labclled human 
mtDNA, were performed as recommended for HybondaN. mtDNA 
was visualised by autoradiography for 24-&h at -70°C. 
2.4. Pul.wt_~rusc chirr twcriott (PCR) ml o/igorrttcl~otid~ prhcrs 
Fragments of mtDNA were amplified from IO0 ng of total DNA 
in a 1011$1 reaction mixture containing 0.5 bM of each primer, 2.5 U 
of Ampli!uq DNA polymcrase (Pcrkin-Elmcr/Cetus), 2OOyM of each 
dNTP, SO mM KCI, IS mM MgC&, IO mM Tris-HCI, pH 8.3, and 
O,OS% g&tin. Following an initial 6 min denaturation step at 92°C. 
the amplification cycles were: I min at 9X, I min at WC and 1 min 
at 72°C. PCR was performed for 30 cycles. After amplification, IO ~1 
of the PCR mixture were electrophorescd through a I .7% a&arose gel 
containing ethidium bromide (0.5 pg/ml). 
The forward (-) primer was located at nucleotidcs (nt) 8196-8215 
(Ll) on the light strand and reverse (-) primers were located at nt 
8726-8707 (Hl) and nt i3524-13506 (HZ) on the heavy strand. The 
Ll and HI primer pair amplified a 530 bp fragment from wild-type 
mtDNA. The LI and H2 primer pair amplilicd a 35 I bp fragment from 
mtDNA possessing the common deletion. To co-amplify both frag 
ments in the same PCR reaction, 0.3 PM of both reverse primers (HI
and H2) were used with 0.5 PM of the forward primer (Ll). Co- 
amplification reactions were performed in triplicate. 
2.5. Smh-d ctfrw for lite cwkmtiotr UJ ilIP cowmtt1 ddetiott 
The wild-type fragment and the fragment from deleted mtDNA 
were amplilied from col,xrol nigral DNA, electrophoresed through a 
1.7% agurose gel, recovered from the gel WA-45 membrane, 
Schleicher and Schuell) and quantitatcd spectrophotometrically t 260 
nm. To a scrics of 6 PCR reaction mixtures (as described in section 
2.4) 0. I, 1, IO, 50,100 and 1,000 pg of template for the deleted mtDNA 
were added along with I ng of template for the wild-type mtDNA. The 
three primers, Ll, HI and H2, were added and the mixtures piked 
with IO&i [OP!dCTP (3.4 pniol). Following co-amplification, frak 
ments were separated by clectrophoresis, and thegel slices correspond- 
ing to the OS3 and 0.351 kb fragments were excised. Radioactivity was 
eluted (Solvable, NEN). counted in a liquid scintillation coun!er. and 
corrected for cytosine content. 
3. RESULTS 
The citrate syzhane-corrected mitochondrial respi- 
ratory chain enzyme activities are shown in Table 1, In 
Parkinson patients there was no significant difference 
from controls for complexes II/III #and IV activities. 
Complex I activity, however, was significantly de- 
creased by 42% of the control mean. There was no 
correlation between zom,plex I activity in Parkinson’s 
disease with L-Dopa treatment, duration of disea:rc :ind 
death 1.0 frep,zing of brain (data not shown). 
Digestion of total DNA from substantia nigra with 
PvuII (Fig. 1) revealed the expecied restriction pattern 
for normal mitochondrial DNA, a single 16.6 kb band. 
?‘he absence of multiple bands or fragment variation 
would indicate that mtDNA from the substantia nigra 
of both PD and control subjects does not possess large 
populations of deleted molecules, Leaving the autora- 
diograph at -7OOC for longer periods failed to show any 
specific smaller bands. 
The more sensitive polymerase chain reaction was 
used to amplify, from 6 PD patients and 6 controls, a 
530 bp fragment from wild-type mtDNA, and 351 bp 
fragment from mtDNA with the 5 kb common deletion. 
The 351 bp fragment was identified as a product of 
deleted mtDNA molecules via nested primer PCR and 
digestion with four restriction enzymes (data not 
shown). On the b;:sis of ethidium bromide staining we 
observed no significant difference in the amount of 351 
bp product between PD paGents and controls (Fig. 2b). 
The 530 bp wild-type fragment was amplified to detect 
variations in the amount of mtDNA in the 100 ng of 
total DNA used for PCR (Fig. 2a). There was no 
notable difference in the amount of normal mtDNA 
between PD patients and controls. 
The relative amourit of the deleted rntDNA was 
estimated by co-amplification of both fragments in the 
same PCR tube as described in section 2. DNA ex- 
tracted from the substantia nigra from 4 PD and 4 
control subjects (subjects PDl-4, Cl-4 Table I) was co- 
amplified and the percentage of mutant mtDNA ~caicu- 
latcd from the ratio of cpm’s in the two fragments 
corrected for cytosine content. The observed per- 
centages of deleted mtDNA were similar in the PD 
Table I 
Mitochondrial respiratory chain cnsymcs correc;:ed for citralc 
synthase activity 
-. .-- 
Complex I Complex 111 Complex IV 
(X100) III (X10) (X100) 
-.. 
Parkinson’s I I .79 I m I.21 
disease 2 I .94 1.26 0.80 
3 I.90 0,85 0.87 
4 1.89 0.66 0.52 
5 I.83 0.86 0.58 
6 2.8i 1.03 0.82 
2.03’ 0.96 0.80 
Ccr. trols 1 3.95 1,12 0.77 
2 3.1/z 0.86 0.88 
3 2*‘32 0.94 0.62 
4 J.S3 I .08 0.81 
5 4.68 1.33 0.96 
6 3.09 I.23 0.93 
3.53 1 .G9 0.83 
‘Significantly lower than in controls: P - 0.004, Mann-Whitney U- 
test 
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1 2 3 4 6 6 7 6 9 10 11 12 kb 
Fig. I. Southern blot of DNA from the substantia nigta of controls, (lanes l-6) and PD patienls (lanes 7-12). DNA samples were digested with 
PuuIl to linearise mtDNA, and probed with normal burnan mtDNA. 
(4.1 + 0.6%) and control patients (4.1 k 0.6%). A stand- 
ard curve was prepared by varying the ratios of the 
purified templates for the deleted and normal molecule, 
to determine the differences in PCR efficiency arising 
from different ratios of normal-to-deleted molecules. As 
the wild-type:mutant ratio decreased the preferential 
amplification of the mutant fragment decreased, giving 
a linear log plot (rs0.97, Fig. 3). Correction for the 
preferential amplification of the mutant fragment was 
achieved by interpolation of the observed values from 
Fig. 3. These she% that there is no significant difference 
in the percentage of mutant mtDNA in the substantia 
nigra between PD and age- matched control subjects, 
and that in the aged human brain, either control or PD, 
approximately l-2 mtDNA molecules in every 10,000 
possess the common deletion (Table II). 
4. DISCUSSION 
The demonstration of mitochondrial complex I de- 
ficiency in the substantia nigra of PD patients has 
focused attention on the possible contribution that 
tntDNA mutations may play in the pathogenesis of this 
disease. mtDNA encodes 7 of the 26 polypeptides of 
complex I and SC an abnormality of mtDNA comp!ex 
I-encoding genes might be expected to contribute to a 
functiona! deficit. The 5 kb common deletion of 
mtDNA, which is found in a variety of diseases as well 
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as being a normal ageing phenomenon, involves genes 
that code for four complex I subunits and so is a pos- 
sible candidate for involvement in PD. Ikebe et a!. [16] 
found the deletion in the striatum from 4 of 5 PD 
patients and 2 of 6 control subjects. Ozawa et al. [14] 
quantified thr deletion from one of these patients and 
suggested it w BS present at a concentration 16-times that 
of control anrl that the deleted mtDNA represented 5% 
of total mtDNA. These results are, however, in contrast 
to studies that have analysed mtDNA in i7D substantia 
nigra by Southern blotting, in which ihere was no 
evidence of any large deletion [12,13]. 
The results of our study described here demonstrate 
that the levels of the common deletion present in PD 
patients and age-matched controls are not significantly 
different. Furthermore, approximately only l-2 in 
10,000 mtDNA molecules bears the tieletion in either 
group. 
The apparent difference between the two sets of data 
may be due to the methods used. We estimated the 
proportion of deleted molecules by eluting and counting 
incorporated radioactivity from the gel bands corre- 
sponding to the r,espective fragments. This avoided 
potential differences in fragment ransfer and hybridisa- 
tion on membranes,, and the non-!ineerity of absorb- 
ance with radioactive signal aad exposure time associ- 
ated with densitometry El7,18]. Also, in our hands, a 
quantifiable xponential increase in PC!F: product by 
Volume 299. number 3 FEBS LETTERS * March 1992 
a. 34 5 6 7 8 61 
b. kb 1 2 34 58 7 8 9101192 
Fig. 2. PCR amplification products of mtDNA from the substarltia 
nigra of PD (lanes l-6) and controls (lanes 7-12), (a) OS3 kb product 
from normal mtDNA. (b) 0.35 kb product from mtDNA possessing 
the common deletion. 
terminating reactions at given cycles (12-34 cycles) was 
not reproducible. This may be due to a combination of 
(i) rate-limiting reaction components (primers dNTP’s, 
enzyme) (ii) the inhibitory effects of product and pyro- 
phosphates, or (iii) tube to tube variation, as noted by 
others [19]. The methods described in this report for the 
estimation of a population of mtDNA can be used for 
comparative studies. 
The difference Ozawa et al. [ 141 observer.1 between PD 
and control DNA was probably due to the difference in 
age between the PD patient (73 years) and control sub- 
ject (38 years) used in their study. An ir;.crease in the 
presence of the 5 kb deletion with age has been reported 
in adult heart [IO] and human liver [20]. I We have also 
detected increased amounts of the deleti’,n with age in 
human skeletal muscle showing a 17”fold increase in the 
common deletion between a 21-year-old and a 7%year- 
old (manuscript in preparation). 
0.0 - ’ I I I I I I I 
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 
Log Initial % of Deleted mtDNA 
Flp, 3. Standard curve for the estimation f the percentage of mtDNA 
possessing the common deletion. 
We conclude that the common deletion is not specific 
to the PD brain and suggest hat the preseuce of the 5 
kb deletion is purely an age-related phenomenon, and 
does not contribute to the pathogenesis of the disease 
nor to the observed complex I deficiency reported in PD 
substantia nigra [7]. Whether the accumulation of the 
deleted genome with age, and a concomitant decrease 
in respiratory chain function, is a primary or secondary 
phenomenon in the ageing process remains to be deter- 
mined. 
It is possible that small deletions and/or mutations 
undetectable on Southern blots may be present and ac- 
cumulate in mtDNA of Parkinson patients, as is the 
case in other neurological diseases (mitochondrial ence- 
phalomyopathies [21,22] and Lebers hereditary optic 
neuropathy [23]). Sequence analysis of mtDNA should 
confirm or exclude the involvement of mitochondrial 
Table II 
Quantitation of the percentage of mtDNA in the substantia nigra lhat possess the common deletion 
.-. 
Agu (yrs.! Observed 8 (mean + SD.) Calculated 8 (range) Mean (calculated) 2 S.D. 
Parkinson’s disease I 71 4.7 ? 0.35 0.0171-lJ.0259 0.0216 r 0.004:: 
: 83 76 4.6 3s‘s ?z 0.50 0.35 0.00?40.01?1  I50- 274 0.0214 .0097 C_+ 0.0062 o oOz9
4 84 3.6 k 0.18 0.0090-0.0118 0.0106 f 0.0014 
4.1 4 0.64 0.0158 f 0.0066 
Controls I 72 3.5 r 0.31 0.0076-0.01?2 0.0096 + 0.0024 
:! 84 4.5 r 0.30 0.0161-0.0237 0.0197 + 0.0038 
3 84 4.6 * 0.31 0.0171-0.0250 0.0205 r O.ciI41 
4 86 3.7 i: 0.17 0.0I05-0.0131 0.01 I4 2 0.0015 
4.6 f 0.56 0.0153 ?r 0.0056 
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genes in mitochondrial dysfunction observed in PD, and 
therefore its role in the pathogenesis of PD. 
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